biologic therapeutic News
-
Confo Therapeutics Enters Collaborative Agreement With Regeneron
Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant conformations, will be ...
-
Alfa Chemistry Releases Functional PEGs for Biological and Therapeutic Research
The compounds conjugated with PEG (functional PEGs) have many advantages. Ever since its discovery, PEGylation is of increasing interest in biological and medical studies owing to their solubility in water, excellent biocompatibility and non-immunogenicity. The US-based chemical supplier Alfa Chemistry announces in a recent statement that it starts to provide functional PEGs for scientific ...
-
SilcsBio and Helix BioStructures Launch Partnership to Collaborate in Fueling Pharmaceutical Drug Design Opportunities
August 29, 2022, Baltimore, MD and Indianapolis, IN – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the launch of a partnership with Helix BioStructures, a pharmaceutical-biotech contract research organization that provides high-quality, integrated drug discovery services to the pharmaceutical community in the ...
-
MOBILion Systems Inc. Announces $60 Million Series C Financing Round Led by D1 Capital Partners to Expand Commercial Activities and Accelerate Product Development
MOBILion Systems Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and biotherapeutic drug characterization, today announced the close of a $60 million Series C financing round. The round was led by D1 Capital Partners with the remaining funds contributed by existing investors aMoon, Agilent Technologies (NYSE:A), IP Group, Hostplus and ...
-
Alex MacKerell, PhD, SilcsBio Co-founder & CSO, Co-Leads Study on Use of SILCS Technology to Improve Lung Disease Treatments
December 14, 2022, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced its Co-Founder and Chief Scientific Officer, Alexander D. MacKerell Jr., PhD, has co-led a study focusing on improving respiratory treatments via SilcsBio’s Site Identification by Ligand Competitive Saturation (SILCS) ...
-
Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem
Alloy Therapeutics, a biotechnology ecosystem company empowering the global scientific community to make better medicines together, today announced the close of a $75 million Series C financing round. The round was led by 8VC, Presight Capital, and Peter Thiel with participation from new investors including Mubadala Capital, the asset management arm of Mubadala Investment Company, an unnamed ...
-
MOBILion Systems Appoints Jenn Buechel to its Board of Directors
MOBILion System Inc. (Chadds Ford, PA), a life science tools and instrumentation company commercializing a best-in-class technology to separate, identify, and analyze the most challenging molecules other instruments fail to detect, announced that it has appointed Jenn Buechel to serve on its Board of Directors, effective immediately. Ms. Buechel, currently the Chief Operating Officer of Delfi ...
-
Obsidian Therapeutics & MD Anderson announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors
Obsidian Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive ...
-
MOBILion Systems Launches MOBIE: The First SLIM-Based High-Resolution Ion Mobility (HRIM) Product to Accelerate Biotherapeutic Drug Development and Multiomic Biomarker Discovery
MOBILion Systems Inc. has today announced the launch of its first commercial High-Resolution Ion Mobility (HRIM) product, MOBIE, which addresses characterization challenges faced during biopharmaceutical drug development and quality monitoring. MOBIE provides fast, efficient separations with superior resolution and reproducibility, faster, simpler method development, and greater instrument ...
-
Lynx Biosciences Appoints Sylvaine Cases, Ph.D., as Chief Business Officer
Lynx Biosciences, Inc. (LynxBio®), a biotechnology company generating unparalleled biological insights through integrated multi-omics, today announced the appointment of Sylvaine Cases, Ph.D., as the company's first Chief Business Officer (CBO). Dr. Cases joins LynxBio from Johnson & Johnson, where she was Vice President of Oncology Strategic Partnering. She brings 20 years of combined ...
-
MOBILion and International Research Team are Awarded Grant from The Michael J. Fox Foundation and the Shake it Up Australia Foundation to Resolve Biomarkers for Parkinson’s Disease
MOBILion Systems, Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and therapeutic development, is collaborating with an international research team to identify alterations in the metabolism of selective glycosphingolipids in specific brain regions that contribute to the early onset and progression of Parkinson’s disease. The ...
-
SANUWAVE Rebrands to Reflect Evolved Wound Care Solutions
SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, today announced its rebranding. The new brand reflects the evolution of SANUWAVE’s solutions addressing the entire wound care pathway through its portfolio of noninvasive and ...
-
Arch Oncology Announces Two New Preclinical Data Presentations on Highly Differentiated Anti-CD47 Antibody AO-176 at AACR 2021
— Two presentations to highlight AO-176’s potential in lymphoma and T-ALL — BRISBANE, CA and ST. LOUIS, MO, March 10, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the presentation of new preclinical data on AO-176 at the American Association for Cancer ...
-
Suono Bio, Inc. Announces Strategic Investment by Fujifilm Corporation
Suono Bio, Inc. announced today a strategic investment by FUJIFILM Corporation to advance Suono Bio’s second-generation platform technology for the ultra-rapid, formulation-independent administration of therapeutics including biologics and gene therapies. Suono Bio leverages technology developed in the laboratory of Institute Professor Robert Langer at the Massachusetts Institute of ...
By Suono Bio
-
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
— Late-breaking presentation highlights preclinical data for AO-176 in T-ALL — BRISBANE, CA and ST. LOUIS, MO, April 10, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the presentation of new preclinical data on AO-176 in pediatric acute lymphoblastic leukemia (T-ALL) ...
-
Promising treatment against COVID-19 and its variants: Quebec biotech, Immune Biosolutions begins Phase I clinical trial stages for its inhaled immunotherapy treatment
Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source. This treatments aims to be ...
-
Sygnature Discovery to Deploy Iktos’s AI for Drug Design Software Makya
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. Under the 3-year agreement, Sygnature will deploy Iktos’ de novo ...
By Iktos
-
Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today the hiring of four senior leaders with significant industry experience in both small and large pharmaceutical and biotech companies. The company plans to continue growing its team to power the expansion of Juvena’s ...
-
Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s ...
-
Terray Therapeutics Expands Leadership Team with Fez Ujjainwalla, PhD as Head of Business and Adam D. Hughes, PhD as Head of Chemistry
Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointments of Feroze (Fez) Ujjainwalla, PhD, as Head of Business, and Adam D. Hughes, PhD, as Head of Chemistry. They join an expanding lineup of industry veterans including Vanessa Taylor, Terray’s Head of Biology and Preclinical Development, Narbe Mardirossian, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you